Last update on February 8, 2023.
Latest News
April 20, 2023
Aptitude Receives up to $54 Million Partnership with BARDA to Develop Diagnostics for Point-of-Care and At-Home Use.
October 18, 2022
Aptitude received FDA Emergency Use Authorization for the Metrix™ COVID-19 Test, the world's first saliva/swab based molecular test for at-home and over-the-counter use without physician supervision.
August 3, 2022
Aptitude submitted request to the FDA for Emergency Use Authorization seeking first saliva/swab based molecular over-the-counter COVID-19 test.
January 27, 2021
Aptitude has received multi-million dollar funding to develop its next-generation molecular diagnostics platform through regulatory approval.
December 21, 2020
Aptitude received California Clinical Laboratory Improvement Amendments (CLIA) license for high-complexity molecular testing.
July 10, 2020
Aptitude was admitted into the prestigious NIH RADx program to develop COVID-19 tests that are easier to use, easier to access, and more accurate.
Latest Events and Attendances
August 2023
Aptitude will attend the annual Military Health System Research Symposium (MHSRS) in Kissimmee, FL.
July 2023
Aptitude will attend the AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim, CA.
March 2023
Aptitude will attend the HIDA Executive Conference in Bonita Springs, FL.
March 2023
Aptitude will attend the LSI Emerging Medtech Summit in Dana Point, CA.
February 2023
Aptitude will attend the 7th SABPA Annual Frontiers in Therapeutics and Diagnostics Forum in Del Mar, CA.
January 2023
Aptitude will attend the J.P. Morgan Healthcare Conference in San Francisco, CA.
September 2022
Aptitude will attend the HIDA Streamlining Healthcare Expo & Business Exchange in Chicago, IL.
August 2022
Aptitude will attend the annual Military Health System Research Symposium (MHSRS) in Kissimmee, FL.
July 2022
Aptitude will attend the AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL.